Lack of correlation between loss of anchorage-independent growth and levels of transformation-specific p53 protein in retinoic acid-treated F9 embryonal carcinoma cells.
It has been shown that differentiated derivatives of retinoic acid (RA)-treated F9 embryonal carcinoma cells become non-malignant. In the present study it is asked whether this loss of malignancy is due to cellular differentiation. Because the ability of cells to grow in suspension correlates with in vivo tumorigenicity, we determined the time course of the loss of this property, after RA treatment, with relation to the differentiation to parietal endoderm and the acquisition of normalcy in several common transformation-specific properties of F9 cells. Our results show that pretreatment with RA for 24 h caused 80% inhibition of anchorage-independent growth in F9 cells, and this inhibition reached its highest level (98%) after pretreatment with RA for 48 h and longer. However, all other observed transformation-related properties, and the levels of plasminogen activator (marker for parietal endoderm) remained unaltered at this early post-treatment stage. These observations suggest that the loss of malignancy is a relatively early event in the biochemical pathways involved in the RA-induced differentiation of F9 cells. Furthermore, our data show that the presence of elevated levels of p53 alone may not be sufficient to maintain the anchorage-independent growth and the rapid proliferation of F9 cells.
Rodrigues
M
M
Balicki
D
D
Newrock
K M
KM
Mukherjee
B B
BB
D000199:Actins / Q000032:analysis; D000818:Animals; D003994:Bucladesine / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D003847:Deoxyglucose / Q000378:metabolism; D054278:Embryonal Carcinoma Stem Cells; D004815:Epidermal Growth Factor / Q000378:metabolism; D066246:ErbB Receptors; D005353:Fibronectins / Q000032:analysis; D051379:Mice; D009363:Neoplasm Proteins / Q000378:metabolism*; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000473:pathology; D010750:Phosphoproteins / Q000378:metabolism*; D010960:Plasminogen Activators / Q000032:analysis; D011956:Receptors, Cell Surface / Q000378:metabolism; D013724:Teratoma / Q000473:pathology; D014212:Tretinoin / Q000494:pharmacology*; D016159:Tumor Suppressor Protein p53
D000199:Actins; D005353:Fibronectins; D009363:Neoplasm Proteins; D010750:Phosphoproteins; D011956:Receptors, Cell Surface; D016159:Tumor Suppressor Protein p53; D014212:Tretinoin; D004815:Epidermal Growth Factor; D003994:Bucladesine; D003847:Deoxyglucose; D066246:ErbB Receptors; D010960:Plasminogen Activators